ESMO 2019 featured the presentation of many interesting studies in the field of lung cancer. Much attention went to non-oncogene driven advanced stage non-small cell lung cancer (NSCLC) in which PD-(L)1 inhibitors are used in monotherapy, in combination with chemotherapy or in combination with CTLA-4 inhibitors. The results of the FLAURA, ALEX and ASCEND-7 trial demonstrated the most recent advances in oncogene-driven advanced stage NSCLC. Finally, the CASPIAN and IMpower 133 trial were the first studies to demonstrate an overall survival benefit with immunotherapy in the field of small-cell lung cancer (SCLC).
